Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice
Eleni Bazigou, … , Nigel A. Brown, Taija Makinen
Eleni Bazigou, … , Nigel A. Brown, Taija Makinen
Published July 18, 2011
Citation Information: J Clin Invest. 2011;121(8):2984-2992. https://doi.org/10.1172/JCI58050.
View: Text | PDF
Research Article Vascular biology

Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice

  • Text
  • PDF
Abstract

Chronic venous disease and venous hypertension are common consequences of valve insufficiency, yet the molecular mechanisms regulating the formation and maintenance of venous valves have not been studied. Here, we provide what we believe to be the first description of venous valve morphogenesis and identify signaling pathways required for the process. The initial stages of valve development were found to involve induction of ephrin-B2, a key marker of arterial identity, by venous endothelial cells. Intriguingly, developing and mature venous valves also expressed a repertoire of proteins, including prospero-related homeobox 1 (Prox1), Vegfr3, and integrin-α9, previously characterized as specific and critical regulators of lymphangiogenesis. Using global and venous valve–selective knockout mice, we further demonstrate the requirement of ephrin-B2 and integrin-α9 signaling for the development and maintenance of venous valves. Our findings therefore identified molecular regulators of venous valve development and maintenance and highlighted the involvement of common morphogenetic processes and signaling pathways in controlling valve formation in veins and lymphatic vessels. Unexpectedly, we found that venous valve endothelial cells closely resemble lymphatic (valve) endothelia at the molecular level, suggesting plasticity in the ability of a terminally differentiated endothelial cell to take on a different phenotypic identity.

Authors

Eleni Bazigou, Oliver T.A. Lyons, Alberto Smith, Graham E. Venn, Celia Cope, Nigel A. Brown, Taija Makinen

×

Figure 4

Prox1 expression in developing and mature venous valves allows genetic targeting of valve endothelial cells in Prox1-CreERT2 mice.

Options: View larger image (or click on image) Download as PowerPoint
Prox1 expression in developing and mature venous valves allows genetic t...
(A and B) Immunofluorescence of ear skin from 3-week-old R26-mTmG;Prox1-CreERT2 (Prox1::GFP) mouse administered 4-OHT at P1. Arrow, lymphatic vessel (GFP+PECAM-1+); arrowhead, blood vessel (GFP–PECAM-1+). (C) Expression of GFP in venous valve of P7 R26-mTmG;Prox1-CreERT2 mouse administered 4-OHT at P1. (D–I) Immunofluorescence staining of iliac veins of R26-mTmG;Prox1-CreERT2 (D and G) and Efnb2GFP (E, F, H, and I) mice at the indicated times using Prox1 antibodies (red). Note GFP expression in the developing valve (arrow) and in vessel wall (asterisk) in R26-mTmG;Prox1-CreERT2 mice after 4-OHT treatment at P0 (D), but more restricted expression in the valve after treatment at P2 (G, arrow). (E, F, H, and I) Arrows, developing venous valves; arrowheads, adjacent lymphatic vessels. (J and K) Immunofluorescence of iliac vein (J) and ear skin (K) from a 4-week-old R26-mTmG;Prox1-CreERT2 mouse fed tamoxifen-containing diet for 2 weeks. (J) Arrows, GFP+ cells on the free edges of valve leaflets; asterisk, recombination in some individual endothelial cells on the vein wall. (K) Arrow, lymphatic vessel (GFP+PECAM-1+); arrowhead, blood vessel (GFP–PECAM-1+). Scale bars: 50 μm (A–I and K); 300 μm (J).

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts